Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | HTR1B | P28222 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | HTR1E | P28566 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13809575 | 0.93 | HDAC1 (0.59) | HDAC1HDAC6AKR1B1POLBGAA | |
| SCHEMBL61089 | 0.91 | HDAC1 (0.53) | HDAC1HDAC6AKR1B1POLBGAA | |
| SCHEMBL61090 | 0.88 | HDAC1 (0.58) | HDAC1HDAC6AKR1B1POLBGAA | |
| SCHEMBL62300 | 0.85 | HDAC1 (0.51) | HDAC1HDAC6AKR1B1POLBGAA | |
| SCHEMBL61297 | 0.84 | HDAC1 (0.63) | HDAC1HDAC6AKR1B1POLBGAA | |
| SCHEMBL62414 | 0.84 | HDAC1 (0.56) | HDAC1HDAC6AKR1B1POLBGAA | |
| SCHEMBL60808 | 0.84 | HDAC1 (0.56) | HDAC1HDAC6AKR1B1POLBGAA | |
| SCHEMBL62788 | 0.84 | HDAC1 (0.53) | HDAC1HDAC6AKR1B1POLBGAA | |
| SCHEMBL68788 | 0.83 | HDAC1 (0.53) | HDAC1HDAC6AKR1B1POLBGAA | |
| SCHEMBL61254 | 0.82 | HDAC1 (0.52) | HDAC1HDAC6AKR1B1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129390-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | claimed |
| EP-2231666-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | claimed |
| WO-2009076631-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | claimed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2231666-B1 | Carboxamide, sulfonamide and amine compounds for metabolic disorders | RIGEL PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-8895578-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895578-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2231666-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2009076631-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076631-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | HDAC1 340/4885HDAC6 277/4885AKR1B1 549/4885 |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | HDAC1 753/4885HDAC6 574/4885AKR1B1 806/4885 |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | CPT2, SHMT2, CS | HDAC1 756/4885HDAC6 532/4885AKR1B1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.